Related by context. All words. (Click for frequent words.) 79 neutropenia 75 febrile neutropenia 74 leukopenia 71 lymphopenia 70 peripheral sensory neuropathy 70 neutropaenia 69 hematologic toxicity 69 neutropenia dehydration dyspnea 67 myelosuppression 67 hypercalcemia 67 leucopenia 67 hypophosphatemia 67 hematologic adverse 66 hypotension 66 severe neutropenia 66 infusion reactions 66 neutropenia thrombocytopenia 66 hypomagnesemia 66 laboratory abnormalities 65 non hematological toxicities 65 Neutropenia 65 hypocalcemia 64 peripheral edema 64 Adverse events 64 hypokalemia 64 dose limiting toxicities 64 pyrexia 64 pyrexia mucositis sepsis febrile 64 nasopharyngitis 64 thrombocytopenia neutropenia 64 stomatitis 63 â ‰ ¥ 63 hematological adverse 63 mucositis 63 hematologic toxicities 63 intracranial hemorrhage ICH 63 gastrointestinal toxicities 63 tumor lysis syndrome 63 neutropenic fever 63 DLTs 63 cytopenias 63 peripheral neuropathy aggravated 63 discontinuations due 63 ALT flares 62 FluCAM arm 62 lopinavir r arm 62 thromboembolic events 62 alanine aminotransferase 62 bone marrow suppression 62 asthenia 62 pruritis 62 hypersensitivity reactions 62 anemia neutropenia 62 severe hypersensitivity reactions 62 elevated ALT 62 pheochromocytoma 62 events AEs 61 4mg/kg 61 renal insufficiency 61 fatigue asthenia 61 hepatotoxicity 61 nephrotoxicity 61 Thrombocytopenia 61 hypersensitivity reaction 61 Infusion Reactions Severe 61 limiting toxicity 61 pancytopenia 61 hepatic encephalopathy 61 incidence ≥ 61 treatment emergent adverse 61 TEAEs 61 transaminase elevations 61 toxicities 61 QTc prolongation 61 Toxicities 61 hematological toxicity 60 AEs 60 myopathy rhabdomyolysis 60 achieved ACR# 60 myalgia arthralgia 60 APTIVUS r 60 acneform rash 60 ≥ 60 PREZISTA r arm 60 renal dysfunction 60 mg/m2 dose 60 gastrointestinal perforation 60 myeloproliferative diseases 60 idiopathic thrombocytopenic purpura 60 dyspnea 60 pruritus 60 neutropenia anemia 59 Hypokalemia 59 REYATAZ r arm 59 evaluable 59 SGPT 59 patients receiving ERBITUX 59 Dermatologic toxicities 59 arterial thromboembolic events 59 PREZISTA r 59 alpha interferons 59 vWD 59 ALT elevations 59 azacitidine 59 hematological toxicities 59 arthralgia 59 constipation nausea 59 sensory neuropathy 59 endophthalmitis 59 thrombocytopenia anemia 59 lactic acidosis 59 hyperkalemia 59 spinal cord compression 59 VAPRISOL 59 nonhematologic adverse reactions 59 esophagitis 59 posaconazole 59 essential thrombocythemia 59 non metastatic osteosarcoma 59 aplastic anemia AA 59 purpura ITP 59 receiving VELCADE 59 myalgia 59 mcg kg 59 haematologic 59 immune thrombocytopenic purpura ITP 59 neutropenic 58 Lupus nephritis 58 Telintra 58 generalized seizures 58 transaminases 58 mg BID 58 diarrhea nausea vomiting 58 liver transaminases 58 #mg/m# [001] 58 EXJADE 58 alkaline phosphatase 58 elevated lipase 58 TORISEL 58 neutropenia febrile neutropenia 58 pleural effusion 58 Febrile neutropenia 58 renal toxicity 58 electrolyte abnormalities 58 fatigue diarrhea nausea 58 platelet counts 58 symptomatic VTE 58 mitoxantrone 58 bacteremia 58 hallucinations dyskinesia 58 concomitant medications 58 mg kg dose 58 pericardial effusion 58 hemorrhagic cystitis 58 proteinuria 58 enterocolitis 58 hepatic dysfunction 58 Lactic acidosis 58 rhinorrhea 58 5-FU/LV 58 nausea vomiting headache 58 splenectomized 58 receiving VICTRELIS 58 neutropenic patients 58 corticosteroid therapy 58 hyperphenylalaninemia HPA due 58 Serious adverse reactions 58 relapsed MM 58 ribavirin therapy 58 anaphylactoid reactions 58 headache abdominal pain 58 chlorambucil 58 chemotherapy induced neutropenia 58 neutrophil count 58 pathologic fractures 58 mg dose 58 extrapyramidal symptoms 57 recurrent VTE 57 unresectable HCC 57 renal impairment 57 TELINTRA 57 HBeAg positive patients 57 non splenectomized 57 elevated serum creatinine 57 TMP SMX 57 plus gemcitabine 57 8mg/kg 57 anterior uveitis 57 proctitis 57 adverse reactions incidence 57 candidemia 57 composite endpoint 57 unknown etiology 57 HBeAg negative patients 57 Eltrombopag 57 mg/m2 57 myalgias 57 Nausea vomiting 57 TNF antagonist 57 HBeAg negative 57 discontinuations 57 del 5q MDS 57 torsade de pointes 57 hepatic failure 57 neuroleptic malignant syndrome 57 DOXIL 57 NEUPOGEN 57 biologic DMARD 57 mucosal inflammation 57 virological failure 57 Ribavirin causes 57 immune thrombocytopenic purpura 57 transaminase elevation 57 CMV infection 57 monotherapy 57 acute GvHD 57 idiopathic thrombocytopenic purpura ITP 57 lymphocytosis 57 delayed CINV 57 adverse reactions irrespective 57 partial remissions 57 steatosis 57 angioedema 57 highly emetogenic 57 virologic breakthrough 57 HbA 1c levels 57 refractory NSCLC 57 p = NS 57 elotuzumab 57 FOLFOX 57 receiving XGEVA 57 thromboembolic 57 dermatologic toxicities 57 antiemetics 57 virologic failure 57 treatment emergent AEs 57 conjunctival hyperemia 56 dermatologic reactions 56 NAGS deficiency 56 Myelosuppression 56 recurrent glioblastoma multiforme 56 serum phosphate 56 von Willebrand disease 56 pneumonitis 56 heparin induced thrombocytopenia 56 PROMACTA 56 peripheral neuropathy 56 tolvaptan 56 piperacillin tazobactam 56 peginterferon alfa 56 arthralgias 56 primidone 56 diarrhea nausea fatigue 56 μg dose 56 somnolence fatigue 56 metastatic GIST 56 experienced hypomagnesemia 56 OADs 56 transaminase 56 Renal impairment 56 DMARDS 56 Erythropoietic therapies may 56 severe hypoglycemia 56 urticaria 56 prolonged QT interval 56 hyperammonemia 56 6 mercaptopurine 56 dasatinib Sprycel ® 56 sarcomas 56 cardiac toxicity 56 mcg kg REBETOL 56 pericardial effusions 56 hemoptysis 56 Elitek 56 ceftriaxone 56 complete remissions 56 epistaxis 56 Hypotension 56 macroalbuminuria 56 mcg BID 56 aspartate aminotransferase 56 CsA 56 cerebrovascular events 56 HES CEL 56 idarubicin 56 hematologic disorders 56 nausea diarrhea 56 oral allopurinol 56 definite stent thrombosis 56 severe hypoglycemic 56 CMV disease 56 FOLFOX4 56 systemic corticosteroid 56 adjunctive ABILIFY 56 CR nPR 56 chronic eosinophilic leukemia 56 grade cervical intraepithelial 56 sarcomatoid 56 thromboembolism 56 orthostatic hypotension 56 paresthesias 56 thrombocytopenic 56 neutrophil counts 56 adverse reactions observed 56 headache nasopharyngitis 56 ara C 56 antibody titers 56 Navelbine 56 unfavorable cytogenetics 56 Hematologic 56 overt nephropathy 56 thrombophlebitis 56 bradycardia 56 mg/# h 56 Known hypersensitivity 56 leukemia AML 56 hepatic enzyme 56 ecchymosis 56 aspartate aminotransferase AST 56 basal cell carcinoma BCC 56 anemia leukopenia 56 plus methotrexate 56 generalized edema 56 thrombotic events 56 refractory gout 56 AST ALT 56 Pharmacokinetics PK 56 thrombocytosis 56 homozygous familial hypercholesterolemia 56 nasopharyngitis headache 56 linezolid 56 erythema redness 56 Vaprisol 55 certolizumab 55 diarrhea vomiting rash 55 interleukin IL -# 55 octreotide LAR 55 hepatic encephalopathy HE 55 liver dysfunction 55 Angioedema 55 thromboembolic complications 55 achieved statistical significance 55 aprepitant 55 post herpetic neuralgia PHN 55 hematologic adverse reactions 55 cilengitide 55 pamidronate 55 Peg IFN 55 P = .# 55 hepatorenal syndrome 55 MADRS score 55 ACTEMRA TM 55 myeloproliferative neoplasms 55 adrenal suppression 55 NATRECOR ® 55 decitabine 55 myelofibrosis polycythemia vera 55 Hypersensitivity reactions 55 extrapyramidal disorder 55 % CI #.#-#.# [007] 55 MALT lymphoma 55 interferon alfa 2b 55 abdominal pain diarrhea 55 FOLPI 55 RBC transfusion 55 FOLFIRI 55 OAB symptoms 55 serum phosphate levels 55 cytopenia 55 anemia thrombocytopenia 55 recurrent genital herpes 55 mucocutaneous reactions 55 events TEAEs 55 neovascular 55 comparator arm 55 RBC transfusions 55 IIIa inhibitor 55 mg QD 55 ATACAND 55 cytogenetic response 55 ARCOXIA 55 ZYVOX 55 ALT elevation 55 ulceration 55 hypervolemic hyponatremia 55 KETEK 55 oral antidiabetic medication 55 angioneurotic edema 55 oral prednisolone 55 endometrial hyperplasia 55 Flu Cy 55 hyperglycemia 55 LEXIVA 55 PRADAXA 55 ACTEMRA 55 ug dose 55 dizziness nausea diarrhea 55 deletion 5q 55 dexamethasone 55 MCyR 55 potent CYP#A# inhibitors 55 secondary hyperparathyroidism 55 #mg BID [001] 55 Sezary syndrome 55 anemia hemoglobin 55 interferon alfa 55 cholecystitis 55 metabolic alkalosis 55 mcg mL 55 voriconazole 55 allogeneic stem cell 55 Zometa hazard 55 fulminant hepatitis 55 GEMZAR 55 symptomatic hypotension 55 severe renal impairment 55 MYCAMINE 55 relapsed multiple myeloma 55 hypoglycemic events 55 neurological manifestations 55 anemia nausea 55 nausea diarrhea constipation 55 splenectomized patients 55 chronic GVHD 55 dysuria 55 HSCT 55 bosentan 55 somnolence sedation 55 severe exacerbations 55 vaccinees 55 gout flares 55 complement inhibitor eculizumab 55 biochemical relapse 55 neoplasm 55 hypereosinophilic syndrome 55 serum aminotransferase levels 55 diarrhea vomiting nausea 55 histologic subtype 55 interstitial lung disease 55 hypoxemia 55 NNT = 55 oxycodone CR 55 metastatic lung cancer 55 IXEMPRA 55 MACCE 55 primary generalized tonic 55 recurrent venous thromboembolism 55 LVEF 55 neurologic symptoms 55 ocular adverse 55 patients evaluable 55 headache diarrhea nausea 55 fluvastatin 55 azathioprine 54 mycophenolate mofetil 54 peginterferon alfa 2b 54 palifermin 54 caspofungin 54 distant metastasis 54 superficial edema 54 heavily pretreated 54 solifenacin 54 immunosuppressive agents 54 severe oral mucositis 54 liver decompensation 54 amprenavir 54 FOLFIRI alone 54 proliferative diabetic retinopathy 54 VIIBRYD 54 heavily pretreated patients 54 postoperative nausea 54 danazol 54 acute renal failure 54 events SAEs 54 teriflunomide 54 BARACLUDE ® 54 weekly subcutaneous injections 54 serum ALT 54 romiplostim 54 thyrotoxicosis 54 invasive candidiasis 54 mg BID dose 54 desvenlafaxine succinate 54 cytogenetic responses 54 triiodothyronine 54 plasma uric acid 54 LPV r 54 pruritus rash 54 confidence interval CI 54 receiving ISENTRESS 54 placebo dexamethasone 54 ascites 54 fluorouracil 54 CR CRu 54 dexamethasone Decadron 54 lenalidomide dexamethasone 54 rituximab 54 chills fever headache 54 saline placebo 54 sulfasalazine 54 haematological toxicity 54 PEGylated anti 54 pomalidomide 54 generalized tonic clonic seizures 54 CIMZIA 54 Discontinuations 54 AGILECT ® 54 vinorelbine 54 hemolysis 54 dapagliflozin plus 54 cytotoxic chemotherapy 54 CIMZIA TM certolizumab pegol 54 myelodysplastic syndrome MDS 54 ertapenem 54 REMICADE ® 54 thrombocytopenic patients 54 tapentadol ER 54 HeFH 54 nephrotoxic 54 oral prodrug 54 bortezomib 54 invasive fungal infections 54 pulmonary toxicity 54 mRCC 54 valsartan amlodipine 54 elevated plasma concentrations 54 triamcinolone 54 leukocytosis 54 serum creatinine levels 54 SAEs 54 gastric ulcers 54 hepatic 54 lupus nephritis 54 metastatic malignant melanoma 54 hA# 54 mcg QD 54 hemolytic anemia 54 HBeAg positive 54 Pred Forte 54 calcineurin inhibitors 54 malignancy HCM 54 vandetanib 54 IGFBP 3 54 imipenem 54 bronchospasm 54 coadministration 54 ipsilateral stroke 54 erythema nodosum 54 QT prolongation 54 tipranavir r 54 mitomycin 54 choroidal neovascularization CNV 54 ventricular fibrillation VF 54 cerebral vasospasm 54 abdominal distension 54 intravascular hemolysis 54 mCi kg 54 etanercept 54 SPRYCEL ® 54 pT3 54 myelofibrosis 54 phenytoin 54 pegylated interferon alfa 2b 54 rFVIIa 54 VELCADE melphalan 54 hyperbilirubinemia 54 steroid dexamethasone 54 dosage regimens 54 evaluable patients 54 orchitis 54 evaluable subjects 54 EBRT 54 pyelonephritis 54 daunorubicin 54 severe hepatomegaly 54 HBeAg seroconversion 54 elevated creatinine 54 myelodysplastic syndromes MDS 54 mg doses 54 cisplatin gemcitabine 54 graft dysfunction 54 pulmonary hypertension PH 54 receiving INTRON 54 docetaxel chemotherapy 54 intravenous bisphosphonates 54 G CSF 54 Primary IGFD 54 moderate renal impairment 54 achieved PASI 54 dysmotility 54 imatinib resistant 54 intermittent claudication 54 serum phosphorous 54 mCRC acneform rash 54 systemic absorption 54 lamotrigine 54 tirofiban 54 AVELOX 54 Torsades de Pointes 54 solar keratoses 54 REVLIMID ® 54 epithelial tumors 54 TNF Tumor Necrosis Factor 54 INFERGEN 54 Tarceva TM 54 Q2W 54 hypoperfusion 54 diarrhea nausea 54 immune mediated 54 haematological 54 adjunctive placebo 54 included neutropenia anemia 54 BENICAR HCT 54 renal allograft 54 lamivudine refractory patients 54 #mg BID [003] 54 intravitreal injections 54 creatinine clearance 54 Fibrillex TM 54 amphotericin B 54 adverse cytogenetics 54 liver histology 54 vasospasm 54 asthenia fatigue 54 ribavirin RBV 54 hypercalcaemia 54 coagulopathy 54 aminotransferases 54 distant metastases 54 EFFEXOR XR 54 vitamin B# folic acid 54 amenorrhoea 54 ARIXTRA 54 abdominal pain headache 54 primary hypercholesterolemia 54 efalizumab 54 gastrointestinal toxicity 53 Fludara 53 gastric adenocarcinoma 53 myelosuppressive chemotherapy 53 postoperative ileus POI 53 ovarian hyperstimulation syndrome OHSS 53 myoclonus 53 urticaria hives 53 potentially hepatotoxic 53 aldosterone antagonist 53 ARICEPT 53 serotonergic drugs 53 Aggrastat ® tirofiban hydrochloride 53 headache nausea fatigue 53 gemcitabine Gemzar ® 53 mEq L 53 XIENCE V PROMUS Stent 53 impaired renal 53 elevated bilirubin 53 isoproterenol 53 tolterodine ER 53 Xanafide 53 pulmonary exacerbations 53 adalimumab 53 PREZISTA ritonavir 53 hepatitis C genotype 53 MULTAQ 53 RPLS 53 COPD exacerbation 53 cutaneous squamous cell carcinoma 53 grade glioma 53 intravenous immunoglobulin 53 myeloablative 53 sunitinib 53 exacerbations 53 rash desquamation 53 Anaphylactic reactions 53 glycated hemoglobin levels 53 recurrent DVT 53 metabolic acidosis 53 PAOD 53 erythropoietic 53 hypercalciuria 53 immunomodulatory therapy 53 lopinavir r 53 hyperactivity impulsivity 53 mcg albinterferon alfa 2b 53 tumor recurrence 53 chronic HBV infection 53 hypersomnia 53 euvolemic 53 nephropathy 53 hypocalcaemia 53 EUFLEXXA R 53 mg/m2/day 53 somnolence dizziness 53 alanine aminotransferase ALT 53 alfa 2a 53 elevated liver enzymes 53 metastatic RCC 53 FOSRENOL ® 53 events thrombocytopenia neutropenia 53 ULORIC 53 umol L 53 intermittent dosing 53 chronic urticaria 53 headache nausea diarrhea 53 cabazitaxel 53 LEXIVA r 53 adverse reactions occurring 53 dose cohort 53 bacteriuria 53 tumor regressions 53 nonfatal MI 53 reinfarction 53 torsades de pointes 53 BUPHENYL 53 anakinra 53 microvascular complications 53 mg/# hours 53 idraparinux 53 mycophenolate mofetil MMF 53 dose cytarabine 53 pharmacokinetic interactions 53 levofloxacin 53 Peripheral edema 53 necrotizing pancreatitis 53 anti leukemic 53 metastatic malignant 53 baseline HbA1c 53 cytogenetic abnormalities 53 MGd 53 nonvertebral fractures 53 akinesia 53 hepatic enzymes 53 Treatment emergent adverse 53 chronic HCV infection 53 serum IGF 53 clodronate 53 Exclusion criteria 53 salmeterol HFA MDI 53 moderately emetogenic 53 invasive aspergillosis 53 INVEGA ® 53 cholestasis 53 myeloproliferative disorder 53 dosed orally 53 atazanavir 53 CIMZIA TM 53 Kidney toxicity nephrotoxicity 53 capillary leak 53 tacrolimus 53 nadolol 53 hepatocellular 53 pruritus itching 53 ‰ ¥ 53 inflammatory lesions 53 akathisia 53 relapsed SCLC 53 headache vomiting 53 adverse reactions ≥ 53 intramuscularly 53 CTAP# Capsules 53 Primary endpoints 53 sUA 53 hemorrhagic complications 53 infection sinusitis 53 zoledronic acid 53 nitrofurantoin 53 β blockers 53 adrenal insufficiency 53 nucleoside analog 53 vesicoureteral reflux 53 PNH patients 53 serum calcium levels 53 5FU 53 low dose cytarabine 53 lamivudine 53 systemic lupus erythematosus SLE 53 nausea vomiting constipation 53 mg ustekinumab 53 ORENCIA 53 acute gout flares 53 postoperative complication 53 NNRTI resistance 53 Myelofibrosis 53 certolizumab pegol 53 ifosfamide 53 Kepivance 53 QD dosing 53 apremilast 53 inducible nitric oxide synthase 53 fatigue abdominal pain 53 coagulation factors 53 Hypocalcemia 53 EDSS scores 53 coinfected patients 53 recurrent ischemia 53 colorectal carcinoma 53 HER2 overexpression 53 cardiac dysfunction 53 tigecycline 53 Hashimoto thyroiditis 53 TYSABRI treated 53 interferon alfa 2a 53 VaD 53 PRADAXA #mg 53 ximelagatran 53 syncope fainting 53 lymphocyte counts 53 stage IIIB 53 bendamustine 53 included exfoliative dermatitis 53 diarrhea headache nausea 53 TNFalpha 53 metastatic renal cell carcinoma 53 hepatic toxicity 53 nausea fatigue 53 CrCl 53 hemolytic 53 diarrhea abdominal pain 53 hyperinsulinemia 53 nicardipine 53 Syndrome RLS 53 dose cohorts 53 VFEND 53 hypopituitarism 53 Venous thromboembolism 53 thromboembolic disease 53 leukemia ALL 53 granisetron 53 pulmonary embolus 53 subclinical hypothyroidism 53 locoregional 53 post herpetic neuralgia 53 μmol L 53 riociguat 53 interstitial pneumonia 53 receiving APTIVUS r 53 methimazole 53 severe rotavirus gastroenteritis 53 MYLOTARG 53 variceal bleeding 53 nausea vomiting headache dizziness 53 CIMZIA ™ 53 visilizumab 53 eculizumab 53 hyperglycaemia 53 hsCRP levels 53 ileus 53 bronchopulmonary dysplasia 53 CINV 53 delayed onset CINV 53 mg q#h 53 mg/# hr 53 dopaminergic therapy 53 ritonavir boosted 53 immunosuppression 53 erythema 53 IRX 2 53 esophageal candidiasis 53 peginterferon 53 primary aldosteronism 53 Secondary endpoints 53 amenorrhea 53 clinically meaningful reductions 53 ZIAGEN 53 INVANZ 53 sinus bradycardia 53 CANCIDAS 52 Keppra R 52 ACTOplus met XR 52 AGILECT R 52 dasatinib 52 prednisone prednisolone 52 thromboses 52 aminotransferase elevations greater 52 beclomethasone dipropionate 52 neurologic dysfunction 52 K ras mutations 52 SSc 52 cIAI 52 ethambutol 52 Neulasta ® 52 abdominal distention 52 Thrombotic events 52 treatment naive genotype 52 CYP #A# 52 relapsing remitting 52 macrovascular events 52 nephrotoxic drugs 52 placebo p = 52 mg kg 52 Exacerbations 52 Myelodysplastic Syndrome MDS 52 hematological parameters 52 swelling edema 52 nitazoxanide 52 potassium sparing diuretics 52 atypical hemolytic uremic syndrome 52 erlotinib Tarceva ® 52 pyridostigmine 52 mucosal healing 52 GnRH agonist 52 adriamycin 52 HbF 52 bacteraemia 52 OHR/AVR# 52 IGFBP 52 cholelithiasis 52 plus octreotide LAR 52 mg m 52 relapsed MCL 52 p = #.# [003] 52 myeloid 52 febuxostat 52 Doxil ® 52 blood dyscrasias 52 log# copies mL 52 bone metastases 52 hematologic abnormalities 52 intravenous bolus 52 induce orthostatic hypotension 52 leiomyomas 52 Clinically significant 52 melphalan prednisone 52 lispro 52 serum potassium 52 chills fatigue 52 Adverse reactions 52 divalproex sodium 52 mixed hyperlipidemia 52 serum sodium 52 TMC# r 52 hematuria 52 hepatocellular carcinomas 52 recurrent UTI 52 imatinib therapy 52 Cutaneous T 52 hyperreflexia 52 rizatriptan 52 plus ribavirin 52 μg doses 52 mitoxantrone plus 52 euvolemic hyponatremia 52 LHRH agonists 52 oral olanzapine 52 bovine thrombin 52 splenic rupture 52 serum phosphorus 52 GH deficiency 52 CIMZIA R 52 levodopa 52 Hepatotoxicity 52 chills headache 52 Nplate 52 insulin detemir 52 cyclophosphamide methotrexate 52 hepatic adverse 52 acromegalic patients 52 Severe hypersensitivity reactions 52 Hematologic toxicity 52 TRAIL R1 52 histologic 52 oral levofloxacin 52 infliximab 52 EGFRIs 52 mouth sores 52 PTLD 52 oxymorphone ER 52 revascularization procedures 52 hemodynamic instability 52 Coadministration 52 mg m² 52 advanced adenomas 52 placebo 52 infection nasopharyngitis 52 SJIA 52 gemifloxacin 52 azathioprine monotherapy 52 purpura 52 lactase deficiency 52 platelet reactivity 52 hypoparathyroidism 52 x ULN 52 forodesine 52 salmeterol fluticasone 52 gastroduodenal 52 serum urate levels 52 liver metastases 52 eosinophilia 52 lupus erythematosus 52 Severe cutaneous 52 anaphylactic reactions bronchospasm 52 advanced adenoma 52 steroid refractory 52 PEGINTRON TM 52 SHPT 52 abciximab 52 asthma exacerbations 52 uncontrolled seizures 52 fever headaches nausea 52 syncope